ScripNews that US Food and Drug Administration Center for Biologics Evaluation and Research (CBER) director Peter Marks submitted his resignation, effective 5 April, late in the day on 28 March shook the b
ScripWith apparently the first death of a patient dosed with its gene therapy Elevidys (delandistrogene moxeparvovec), Sarepta incurred a significant reduction in its stock price on 18 March, as well as qu
ScripAnalysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US
ScripBridgeBio Oncology Therapeutics (BBOT), the cancer drug company spun out of rare disease-focused BridgeBio Pharma in May 2024 with $200m in venture capital financing, announced on 28 February that it